| Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist HS Taylor, LC Giudice, BA Lessey, MS Abrao, J Kotarski, DF Archer, ... New England Journal of Medicine 377 (1), 28-40, 2017 | 489 | 2017 |
| Long-term outcomes of elagolix in women with endometriosis: results from two extension studies E Surrey, HS Taylor, L Giudice, BA Lessey, MS Abrao, DF Archer, ... Obstetrics & Gynecology 132 (1), 147-160, 2018 | 123 | 2018 |
| Dose-dependent suppression of gonadotropins and ovarian hormones by elagolix in healthy premenopausal women J Ng, K Chwalisz, DC Carter, CE Klein The Journal of Clinical Endocrinology & Metabolism 102 (5), 1683-1691, 2017 | 119 | 2017 |
| Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation P Jacobson, J Rogosheske, JN Barker, K Green, J Ng, D Weisdorf, Y Tan, ... Clinical Pharmacology & Therapeutics 78 (5), 486-500, 2005 | 95 | 2005 |
| Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study DF Archer, EA Stewart, RI Jain, RA Feldman, AS Lukes, JD North, ... Fertility and sterility 108 (1), 152-160. e4, 2017 | 91 | 2017 |
| Factors affecting the pharmacokinetics of tacrolimus (FK506) in hematopoietic cell transplant (HCT) patients P Jacobson, J Ng, V Ratanatharathorn, J Uberti, RC Brundage Bone marrow transplantation 28 (8), 753-758, 2001 | 88 | 2001 |
| Posttransplant day significantly influences pharmacokinetics of cyclosporine after hematopoietic stem cell transplantation PA Jacobson, J Ng, KGE Green, J Rogosheske, R Brundage Biology of blood and marrow transplantation 9 (5), 304-311, 2003 | 62 | 2003 |
| Pharmacokinetic enhancement in HIV antiretroviral therapy: a comparison of ritonavir and cobicistat. B Renjifo, J van Wyk, A Hamed Salem, D Bow, J Ng, M Norton AIDS reviews 17 (1), 2015 | 57 | 2015 |
| Clinical pharmacology of elagolix: an oral gonadotropin-releasing hormone receptor antagonist for endometriosis M Shebley, AR Polepally, A Nader, JW Ng, I Winzenborg, CE Klein, ... Clinical pharmacokinetics 59 (3), 297-309, 2020 | 49 | 2020 |
| A limited sampling model for estimation of total and unbound mycophenolic acid (MPA) area under the curve (AUC) in hematopoietic cell transplantation (HCT) J Ng, J Rogosheske, J Barker, D Weisdorf, PA Jacobson Therapeutic drug monitoring 28 (3), 394-401, 2006 | 35 | 2006 |
| Population pharmacokinetics of elagolix in healthy women and women with endometriosis I Winzenborg, A Nader, AR Polepally, M Liu, J Degner, CE Klein, ... Clinical pharmacokinetics 57, 1295-1306, 2018 | 28 | 2018 |
| Elagolix suppresses ovulation in a dose-dependent manner: results from a 3-month, randomized study in ovulatory women DF Archer, J Ng, K Chwalisz, YL Chiu, EC Feinberg, CE Miller, ... The Journal of Clinical Endocrinology & Metabolism 105 (3), 821-832, 2020 | 25 | 2020 |
| The effect of food on ritonavir bioavailability following administration of ritonavir 100 mg film-coated tablet in healthy adult subjects CE Klein, YL Chiu, W Awni, J Ng, Y Cui, J Morris, T Podsadecki, D Kim, ... Age (years) 30 (10.9), 20-55, 2008 | 25 | 2008 |
| Quantitative assessment of elagolix enzyme-transporter interplay and drug–drug interactions using physiologically based pharmacokinetic modeling MS Chiney, J Ng, JP Gibbs, M Shebley Clinical Pharmacokinetics 59 (5), 617-627, 2020 | 20 | 2020 |
| Assessment of clinical drug‐drug interactions of elagolix, a gonadotropin‐releasing hormone receptor antagonist AR Polepally, JW Ng, AH Salem, MB Dufek, A Parikh, DC Carter, ... The Journal of Clinical Pharmacology 60 (12), 1606-1616, 2020 | 15 | 2020 |
| Elagolix pharmacokinetic profiles in women with renal or hepatic impairment J Ng, WR Duan, T Marbury, JM Schmidt, CE Klein Clinical Pharmacology in Drug Development 8 (8), 1053-1061, 2019 | 14 | 2019 |
| Exposure‐safety analyses identify predictors of change in bone mineral density and support elagolix labeling for endometriosis‐associated pain A Abbas Suleiman, A Nader, I Winzenborg, D Beck, AR Polepally, J Ng, ... CPT: Pharmacometrics & Systems Pharmacology 9 (11), 639-648, 2020 | 12 | 2020 |
| Methods of adminstering elagolix SL Goss, CE Klein, JWK Ng, A Salem US Patent 9,949,974, 2018 | 12 | 2018 |
| Methods of treating heavy menstrual bleeding K Chwalisz, LA Williams, RI Jain, JD North, JWK Ng US Patent 10,881,659, 2021 | 9 | 2021 |
| EFFECTS OF THE COADMINISTRATION OF SINGLE AND MULTIPLE DOSES OF RIFAMPIN ON THE PHARMACOKINETICS AND SAFETY OF ELAGOLIX IN HEALTHY PREMENOPAUSAL FEMALES. J Ng, A Salem, D Carter, LA Williams, CE Klein Clinical Pharmacology & Therapeutics 99, S54-S55, 2016 | 9 | 2016 |
